Following its blueprint

Why Nextech co-led a $94M series B for synthetic lethality play Ideaya

Ideaya Biosciences Inc.’s goal of developing treatments for genomically defined subsets of cancer patients led Nextech Invest to co-lead the company’s $94 million series B round.

Nextech, 6 Dimensions Capital, BVF Partners and Perceptive Advisors led the untranched round, joined

Read the full 392 word article

User Sign In